Sionna keeps two CF trial readouts on track for summer 2026

Sionna Therapeutics reported second-quarter 2026 financial results and a pipeline update on August 6, 2026. The company said its PreciSION CF Phase 2a proof-of-concept trial, registered as NCT07108153, is testing SION-719 as an add-on to standard of care in CF patients, looking at safety, tolerability, pharmacokinetics, and change in sweat chloride as a measure of CFTR function.¹ Sionna noted that enrollment for that trial was completed in April 2026, with topline data still expected this summer.¹

The company also gave an update on its Phase 1 dual combination study. The trial, listed as NCT07035990, is testing SION-451 paired separately with SION-2222 (galicaftor), a TMD1-directed CFTR corrector, and with SION-109, an ICL4-directed CFTR corrector, in healthy volunteers.¹ Topline data from that study are also on track for this summer.¹

On the conference front, Sionna presented supplemental clinical and preclinical findings under the title "49th European Cystic Fibrosis Conference" in Lisbon in June 2026. The presentations covered previously disclosed Phase 1 results for SION-719 and SION-451, along with nonclinical work showing that NBD1 stabilizers could raise F508del-CFTR protein half-life to wild-type levels, alone or paired with other CFTR modulators.¹ The same data are set to be shown at the 16th Australasian Cystic Fibrosis Conference, running August 7 to 9 in Geelong, Australia.¹

On finances, Sionna held $268.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, which the company said is enough to fund operations into 2028.¹